DOCSLIB.ORG

Lung Systemic Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lung Systemic Treatment June 2019 Missouri Cancer Registry and Research Center Ed 19:02 Lung Show-Me-Tips Coding...Abstracting...Education… Coding Systemic Therapy Lung Cancer Systemic Therapy Non-Small Cell Lung Cancer Chemotherapy Subcategory Abraxane (Protein-bound Paclitaxel) Taxane Afinitor (Everolimus) Cytostatic agent--antiangiogenesis agent and mTOR inhibitor Alectinib (Alecensa) ALK Inhibitor Brigatinib (Alunbrig) Anaplastic lymphoma kinase Carboplatin (Paraplatin) Alkylating agent , Platinum analog Ceritinib (Zykadia) ALK tyrosine kinase inhibitor Crizotinib (Xalkori) Kinase inhibitor, Target- ed therapy anaplastic lymphoma kinase Erlotinib (Tarceva, Erlotinib Hydrochloride) Cytostatic agent--tyrosine kinase inhibitor, EGF inhibitor Docetaxel (Taxotere) Taxane Gefitinib (Iressa) Cytostatic agent--tyrosine kinase inhibitor Gilotrif (Afatinib) Tyrosine kinase inhibitor Gemcitabine (Gemzar) Antimetabolite Irinotecan (Camptosar) Topoisomerase inhibitor Mechlorethamine (Mustargen, Nitrogen Mustard) Alkylating agent Methotrexate (Folex, Mexate) Antimetabolite Paclitaxel (Taxol) Mitotic inhibitor, plant alkaloid, Taxane Pemetrexed (Alimta) Antimetabolite Tagrisso (Osimertinib) EGFR-TKI inhibitor Vinorelbine (Navelbine) Plant alkyloid Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 1 June 2019 Missouri Cancer Registry and Research Center Ed 19:02 Lung Show-Me-Tips Coding...Abstracting...Education… Coding Systemic Therapy Lung Cancer Systemic Therapy Small Cell Lung Cancer Chemotherapy Only Subcategory Afinitor (Everolimus) Cytostatic agent--antiangiogenesis agent and mTOR inhibitor Doxorubicin (Adriamycin) Antitumor antibiotic Etoposide (Eposine, Etopophos) Epipodophyllotoxin, topoisomerase II inhibitor, Plant alkaloid Irinotecan (Camptosar) + Cisplatin or Carboplatin Topoisomerase inhibitor Mechlorethamine (Mustargen, Nitrogen Mustard) Alkylating agent Methotrexate (Folex, Mexate) Antimetabolite Topotecan (Hycamtin) Topoisomerase inhibitor Biological Response Modifiers Subcategory Atezolizumab* (Tecentriq, MPDL3208A) Monoclonal antibody Bevacizumab (Avastin) Cytostatic agent--antiangiogenesis agent, Recombinant human anti-VEGF, Vascular endothelial growth factor receptor inhibitor Cyramza (Ramucirumab) Antiangiogenesis, Monoclonal antibody Durvalumab* (Imfinzi) FDA approved 2/18 None Keytruda (Pembrolizumab) approved 10/18 Monoclonal antibody Necitumumab (Portrazza) Anti-EFRG monoclonal antibody Nivolumab* (Opdivo) braf inhibitor * PD-L1 inhibitors: interacts with the Common drug combinations PD-1 protein on T cells Carboplatin & Taxol Gemzar & Cisplatin Adapted from the presentation “Coding Systemic Treatment” and used with permission of Mary B. Davidson, RN, BSN, MN, CTR Source: “Coding Systemic Treatment” presented at the 2018 NCRA conference by Mary B. Davidson, RN, BSN, MN, CTR This project was supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (NU58DP006299-02) and a Surveillance Contract between DHSS and the University of Missouri. 2 .
Load more

Recommended publications
  • Selective DNA-Pkcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy
    Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy Catherine E. Willoughby, … , Anderson J. Ryan, Stephen R. Wedge J Clin Invest. 2019. https://doi.org/10.1172/JCI127483. Research Article Oncology Therapeutics Graphical abstract Find the latest version: https://jci.me/127483/pdf The Journal of Clinical Investigation RESEARCH ARTICLE Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy Catherine E. Willoughby,1 Yanyan Jiang,2 Huw D. Thomas,1 Elaine Willmore,1 Suzanne Kyle,1 Anita Wittner,1 Nicole Phillips,1 Yan Zhao,1 Susan J. Tudhope,1 Lisa Prendergast,1 Gesa Junge,1 Luiza Madia Lourenco,2 M. Raymond V. Finlay,3 Paul Turner,3 Joanne M. Munck,4 Roger J. Griffin,5 Tommy Rennison,5 James Pickles,5 Celine Cano,5 David R. Newell,1 Helen L. Reeves,1,6 Anderson J. Ryan,2 and Stephen R. Wedge1 1Cancer Research UK Newcastle Drug Discovery Unit, Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom. 2Cancer Research UK and UK Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford, United Kingdom. 3Medicinal Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom. 4Astex Pharmaceuticals, Cambridge, United Kingdom. 5Cancer Research UK Newcastle Drug Discovery Unit, Chemistry, School of Natural and Environmental Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom. 6Hepatopancreatobiliary Multidisciplinary Team, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom. Potentiating radiotherapy and chemotherapy by inhibiting DNA damage repair is proposed as a therapeutic strategy to improve outcomes for patients with solid tumors.
    [Show full text]
  • Page 1 EXAMPLES of ACUTE TOXINS (By CAS#) APPENDIX V(H)-B
    EXAMPLES OF ACUTE TOXINS (by CAS#) APPENDIX V(h)-B Key: SA -- Readily Absorbed Through the Skin Revised: 12/2012 ___________________________________________________ _____________ _________________________ | | | CHEMICAL NAME CAS # | SA | TARGET ORGAN | ___________________________________________________ ____________ | _ | _______________________ | AFLATOXINS 000000-00-0 | | systemic | ANILINE AND COMPOUNDS 000000-00-0 | x | blood | ARSENIC ACID AND SALTS 000000-00-0 | x | systemic | ARSENIUOS ACID AND SALTS 000000-00-0 | | systemic | ARSONIC ACID AND SALTS 000000-00-0 | | systemic | BOTULINUM TOXINS 000000-00-0 | | systemic | CYANIDE AND COMPOUNDS 000000-00-0 | x | blood | CYANOGEN AND COMPOUNDS 000000-00-0 | | blood | METHYL MERCURY AND COMPOUNDS 000000-00-0 | x | CNS | VENOM, SNAKE, CROTALUS ADAMANTEUS 000000-00-0 | | systemic | VENOM, SNAKE, CROTALUS ATROX 000000-00-0 | | systemic | MITOMYCIN C 000050-07-7 | | systemic | DINITROPHENOL, 2,4- 000051-28-5 | x | systemic | ATROPINE 000051-55-8 | x | CNS | HN2 (NITROGEN MUSTARD-2) 000051-75-2 | x | systemic | THIOTEPA 000052-24-4 | | systemic | NICOTINE 000054-11-5 | x | CNS | NITROGEN MUSTARD HYDROCHLORIDE 000055-86-7 | x | systemic | PARATHION 000056-38-2 | x | CNS | CYANIDE 000057-12-5 | x | blood | STRYCHNINE 000057-24-9 | | systemic,CNS | TUBOCURARINE CHLORIDE HYDRATE,(+)- 000057-94-3 | x | systemic | METHYL HYDRAZINE 000060-34-4 | x | pulmonary,CNS,blood | ANILINE 000062-53-3 | x | blood | DICHLORVOS 000062-73-7 | x | systemic | SODIUM FLUOROACETATE 000062-74-8 | x | systemic | COLCHICINE
    [Show full text]
  • Human Cytogenetics Prenatal Diagnostics
    Cytogenetics Human Cytogenetics Prenatal Diagnostics Optimized Medium for Culture and Genetic Analysis of Human Amniotic Fluid Cells BIOAMF-1 and Chorionic Villi ( CV ) Samples Basal Medium and Supplement Chromosome Karyotyping was first developed in the BIOAMF-1 is designed for the primary culture of field of Cytogenetics. human amniotic fluid cells and chorionic villi (CV) The basic principle of the method is the preparation samples in both open (5% CO2) and closed systems. of chromosomes for microscopic observation by The medium allows rapid growth of amniocytes or arresting cell mitosis at metaphase with colchicine and treating the cells with a hypotonic solution. This chorionic villi for use in karyotyping. is followed by regular or fluorescent staining of the No supplementation with serum or serum- chromosomes, which are then tested with the aid of a substitutes is necessary. microscope and computer programs to arrange and The medium consists of two components: basal identify the chromosomes for the presence of genetic medium and frozen supplements. abnormalities. In principle, this method enables the identification Instructions for Use of any abnormality - excess chromosomes or For the preparation of 500ml complete medium, use chromosome deficiency, broken chromosomes, 01-190-1A with 01-192-1E. or excess genetic material (as a result of a For the preparation of 100ml complete medium, use recombination process). 01-190-1B with 01-192-1D. Clinical cytogenetics laboratories use this method Thaw the BIOAMF-1 Supplement by swirling in a with amniotic fluid, chorionic villi, blood cells, skin cells, and so on, which can be cell cultured to obtain 37ºC water bath, and transfer the contents to the mitotic cells.
    [Show full text]
  • Anti-Neoplastic Effects of Topoisomerase Inhibitors in Canine Mammary Carcinoma, Melanoma, and Osteosarcoma Cell Title Lines
    Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell Title lines Ong, Siew Mei; Yamamoto, Hiroki; Saeki, Kohei; Tanaka, Yuiko; Yoshitake, Ryohei; Nishimura, Ryohei; Nakagawa, Author(s) Takayuki Citation Japanese Journal of Veterinary Research, 65(1), 17-28 Issue Date 2017-02 DOI 10.14943/jjvr.65.1.17 Doc URL http://hdl.handle.net/2115/64788 Type bulletin (article) File Information 65-1_017-028.pdf Instructions for use Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP Japanese Journal of Veterinary Research 65(1): 17-28, 2017 REGULAR PAPER Experimental Research Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines Siew Mei Ong1,†), Hiroki Yamamoto1,†), Kohei Saeki1), Yuiko Tanaka1), Ryohei Yoshitake1), Ryohei Nishimura1) and Takayuki Nakagawa1,＊) 1) Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan Received for publication, November 29, 2016; accepted, December 27, 2016 Abstract Numerous topoisomerase inhibitors with proven efficacy have been used extensively to treat various human neoplasms. However, among these, only doxorubicin has been used and studied extensively in veterinary oncology. The current study was performed to evaluate the responsiveness of canine osteosarcoma (cOSA), mammary gland tumour (cMGT), and malignant melanoma (cMM) cell lines to several topoisomerase inhibitors. In addition, the correlation between the sensitivity to treatment and multi-drug resistant (MDR) factors was investigated. cOSA cell lines exhibited higher sensitivity than cMGT and cMM cell lines to all the topoisomerase inhibitors tested in vitro; this was associated with the levels of multi-drug resistance protein 1 (MDR1) gene expression in the cOSA cell lines.
    [Show full text]
  • The Chemotherapy of Malignant Disease -Practical and Experimental Considerations
    Postgrad Med J: first published as 10.1136/pgmj.41.475.268 on 1 May 1965. Downloaded from POSTGRAD. MED. J. (1965), 41,268 THE CHEMOTHERAPY OF MALIGNANT DISEASE -PRACTICAL AND EXPERIMENTAL CONSIDERATIONS JOHN MATTHIAS, M.D., M.R.C.P., F.F.A., R.C.S. Physician, The Royal Marsden Hospital, London, S.W.3. THE TERM chemotherapy was introduced by positively charged alkyl (CH2) radicles of Ehrlich to describe the specific and effective the agent. treatment of infectious disease by chemical (a) The nitrogen mustards: mustine (HN2 substances. It is currently also applied to the 'nitrogen mustard', mechlorethamine, treatment of malignant disease. Unfortunately mustargen), trimustine (Trillekamin no aspect of tumour metabolism has been HN3), chlorambucil (Leukeran, phenyl discovered which has allowed the development butyric mustard), melphalan (Alkeran, of drugs capable of acting specifically upon the phenyl alanine mustard), uramustine malignant cell, so that cytotoxic drugs also (Uracil mustard), cyclophosphamide affect normal cells to a greater or lesser degree. (Endoxan or Cytoxan), mannomustine The most susceptible or sensitive of the normal (DegranoO). tissues are those with the highest rates of cell (b) The ethylenamines: tretamine (trie- turnover and include the haemopoietic and thanomelamine, triethylene melamine, lympho-reticular tissues, the gastro-intestinal TEM), thiotepa (triethylene thiopho- the the testis and the hair epithelium, ovary, sphoramide), triaziquone (Trenimon).by copyright. follicles. (c) The epoxides: triethyleneglycoldigly- Cancer chemotherapy may be said to encom- cidyl ether (Epodyl). pass all treatments of a chemical nature (d) The sulphonic acid esters: busulphan administered to patients with the purpose of (Myleran), mannitol myleran. restricting tumour growth or destroying tumour 2.
    [Show full text]
  • CLINICAL and PHARMACOLOGICAL STUDIES on the TOPOISOMERASE I INHIBITOR TOPOTECAN Cover Design: G.L.M
    CLINICAL AND PHARMACOLOGICAL STUDIES ON THE TOPOISOMERASE I INHIBITOR TOPOTECAN Cover design: G.L.M. Obbens Lay-out: A.A.C. Treuren-den Braber Printed by: Copynomie Erasmus Multicopy Facility Management B.V. Burg. Oudlaan 50 3062 PA Rotterdam The Netherlands phone: 010-4082898 fax: 010-4528183 ISBN: 9090091718 Copyright: G.J. Creemers. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanically, by photocopying, by recording or otherwise without the prior permission of the author. Clinical and pharmacological studies on the topoisomerase I inhibitor topotecan Klinisch en farmacologisch onderzoek met de topoisomerase I rammer topotecan. PROEFSCHRIFT ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof. dr. P.W.C. Akkermans M.A. en volgens besluit van het college voor promoties. De open bare verdediging zal plaatsvinden op woensdag 13 maart 1996 om 13.45 uur door Gerardus Johannes Marie Creemers geboren te Eindhoven PROMOTIECOMMISSIE Promotor: Prof. dr. G. Stoter Copromotor: Dr. J. Verweij Overige leden: Prof. dr. D.O. Von Hoff Prof. dr. J.H. Beijnen Prof. dr. J.W. Oosterhuis Prof. dr. A. Hagenbeek "Aileen wat niet ophoudt pijn te doen, blijft in de herinnering" Contents Chapter 1 Introduction to the thesis. 1 Chapter 2 Review: The topoisomerase I inhibitors topotecan and irinotecan. 5 Cancer Treatment Reviews 1994: 20; 73·96. Chapter 3 Topotecan in colorectal cancer: A phase II study of the EORTe clinical trials group. 47 Annals of oncology 1995: 6; 844·846.
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Differential Effects of the Poly (ADP-Ribose)Polymerase (PARP
    British Journal of Cancer (2001) 84(1), 106–112 © 2001 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1555, available online at http://www.idealibrary.com on http://www.bjcancer.com Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro KJ Bowman*, DR Newell, AH Calvert and NJ Curtin Cancer Research Unit, University of Newcastle upon Tyne Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK Summary The potent novel poly(ADP-ribose) polymerase (PARP) inhibitor, NU1025, enhances the cytotoxicity of DNA-methylating agents and ionizing radiation by inhibiting DNA repair. We report here an investigation of the role of PARP in the cellular responses to inhibitors of topoisomerase I and II using NU1025. The cytotoxicity of the topoisomerase I inhibitor, camptothecin, was increased 2.6-fold in L1210 cells by co-incubation with NU1025. Camptothecin-induced DNA strand breaks were also increased 2.5-fold by NU1025 and exposure to camptothecin-activated PARP. In contrast, NU1025 did not increase the DNA strand breakage or cytotoxicity caused by the topoisomerase II inhibitor etoposide. Exposure to etoposide did not activate PARP even at concentrations that caused significant levels of apoptosis. Taken together, these data suggest that potentiation of camptothecin cytotoxicity by NU1025 is a direct result of increased DNA strand breakage, and that activation of PARP by camptothecin-induced DNA damage contributes to its repair and consequently cell survival. However, in L1210 cells at least, it would appear that PARP is not involved in the cellular response to etoposide-mediated DNA damage.
    [Show full text]
  • Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
    cancers Review Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer Lukas Gorecki 1 , Martin Andrs 1,2 and Jan Korabecny 1,* 1 Biomedical Research Center, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic; [email protected] (L.G.); [email protected] (M.A.) 2 Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 00 Prague, Czech Republic * Correspondence: [email protected]; Tel.: +420-495-833-447 Simple Summary: Selective killing of cancer cells is privileged mainstream in cancer treatment and targeted therapy represents the new tool with a potential to pursue this aim. It can also aid to overcome resistance of conventional chemo- or radio-therapy. Common mutations of cancer cells (defective G1 control) favor inhibiting intra-S and G2/M-checkpoints, which are regulated by ATR–CHK1–WEE1 pathway. The ATR–CHK1–WEE1 axis has produced several clinical candidates currently undergoing clinical trials in phase II. Clinical results from randomized trials by ATR and WEE1 inhibitors warrant ongoing clinical trials in phase III. Abstract: Selective killing of cancer cells while sparing healthy ones is the principle of the perfect cancer treatment and the primary aim of many oncologists, molecular biologists, and medicinal chemists. To achieve this goal, it is crucial to understand the molecular mechanisms that distinguish cancer cells from healthy ones. Accordingly, several clinical candidates that use particular mutations in cell-cycle progressions have been developed to kill cancer cells. As the majority of cancer cells have defects in G1 control, targeting the subsequent intra-S or G2/M checkpoints has also been extensively Citation: Gorecki, L.; Andrs, M.; pursued.
    [Show full text]
  • Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance
    cells Review Functional Genomics Approaches to Elucidate Vulnerabilities of Intrinsic and Acquired Chemotherapy Resistance Ronay Cetin 1,† , Eva Quandt 2,† and Manuel Kaulich 1,3,4,* 1 Institute of Biochemistry II, Goethe University Frankfurt-Medical Faculty, University Hospital, 60590 Frankfurt am Main, Germany; [email protected] 2 Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, 08195 Barcelona, Spain; [email protected] 3 Frankfurt Cancer Institute, 60596 Frankfurt am Main, Germany 4 Cardio-Pulmonary Institute, 60590 Frankfurt am Main, Germany * Correspondence: [email protected]; Tel.: +49-(0)-69-6301-5450 † These authors contributed equally to this work. Abstract: Drug resistance is a commonly unavoidable consequence of cancer treatment that results in therapy failure and disease relapse. Intrinsic (pre-existing) or acquired resistance mechanisms can be drug-specific or be applicable to multiple drugs, resulting in multidrug resistance. The presence of drug resistance is, however, tightly coupled to changes in cellular homeostasis, which can lead to resistance-coupled vulnerabilities. Unbiased gene perturbations through RNAi and CRISPR technologies are invaluable tools to establish genotype-to-phenotype relationships at the genome scale. Moreover, their application to cancer cell lines can uncover new vulnerabilities that are associated with resistance mechanisms. Here, we discuss targeted and unbiased RNAi and CRISPR efforts in the discovery of drug resistance mechanisms by focusing on first-in-line chemotherapy and their enforced vulnerabilities, and we present a view forward on which measures should be taken to accelerate their clinical translation. Citation: Cetin, R.; Quandt, E.; Kaulich, M. Functional Genomics Keywords: chemotherapy resistance; cancer and drug vulnerabilities; functional genomics; RNAi Approaches to Elucidate Vulnerabilities of Intrinsic and and CRISPR screens Acquired Chemotherapy Resistance.
    [Show full text]
  • Salvage Chemotherapy for Recurrent Primary Brain Tumors in Children
    Salvage chemotherapy for recurrent primary brain tumors in children Jan van Eys, PhD, MD, Tallie Z. Baram, MD, PhD, Ayten Cangir, MD, Janet M. Bruner, MD, and J. Martinez-Prieto, MD From the Departments of Pediatrics, Neurooncology, and Pathology, The Universityof Texas M, D. Anderson Cancer Center at Houston Sixty consecutive evaluable children with recurrent primary tumors of the central nervous system were treated with a regimen of vincristine, nitrogen mustard, procarbazine, and prednisone over a 12-year period. Tumor types included medulloblastoma (19), brain-stem glioma (16), astrocytoma (13), and a miscellaneous glioma (12). Responses and sustained survivals were achieved. Responses were highly dependent on tumor type. Disease progres- sion was halted in 73% of the children with medulloblastoma, and three have survived in complete remission for more than 10 years from the start of therapy with vincristine, nitrogen mustard, procarbazine, and prednisone. Two of four patients with anaplastic glioma, are long-term survivors. In contrast, less than one third of children with brain-stem gliomas responded. Toxicity consisted mainly of neutropenia, thrombocytopenia, infections, and rarely a procarba- zine rash. (J PEDIAI'R1988;113:601-6) Therapy for recurrent brain tumors in children remains METHODS unsatisfactory; most die of their disease regardless of Patients. Sixty-five children with a median age of 6 therapy, l We have repbrted on the responsiveness of years (range, 1 to 16 years) were treated with MOPP for recurrent brain tumors in children to chemotherapy with recurrent brain tumors. Sixty patients were eligible for vincristine, nitrogen mustard, procarbazine, and predni- evaluation; the other five patients were excluded because 1 sone.
    [Show full text]
  • As New Horizons in Antifungal Treatment
    molecules Review ‘Acridines’ as New Horizons in Antifungal Treatment Iwona Gabriel Department of Pharmaceutical Technology and Biochemistry, Gda´nskUniversity of Technology, 80-233 Gda´nsk, Poland; [email protected]; Tel.: +48-58-3486-078; Fax: +48-58-3471-144 Received: 18 February 2020; Accepted: 23 March 2020; Published: 25 March 2020 Abstract: Frequent fungal infections in immunocompromised patients and mortality due to invasive mycosis are important clinical problems. Opportunistic pathogenic Candida species remain one of the leading causes of systemic mycosis worldwide. The repertoire of antifungal chemotherapeutic agents is very limited. Although new antifungal drugs such as lanosterol 14α-demethylase and β-glucan synthase inhibitors have been introduced into clinical practice, the development of multidrug resistance has become increasingly significant. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets to the conventional ones currently used. Among them, many compounds containing an acridine scaffold have been synthesized and tested. In this review, the applicability of acridines and their functional analogues acridones as antifungal agents is described. Acridine derivatives usage in photoantifungal chemotherapy, interactions with fungal transporters resulting in modulation of efflux/influx pumps and the effect of acridine derivatives on fungal topoisomerases are discussed. This article explores new perspectives
    [Show full text]